



**Technology and Science-Directed
Regulation:
Product-Based vs. Process-Based Regulation**

Brasilia, Brazil

August, 2014

Harlan Howard, Brinda Dass, and Larisa Rudenko

On behalf of the

**Animal Biotechnology Interdisciplinary Group
Center for Veterinary Medicine
U.S. Food and Drug Administration**

Goal ...

Briefly discuss the underlying approaches for the U.S. “product-based” vs. “process-based” regulation, with focus on GE animals

Overview

- Coordinated Framework for Regulation of Biotechnology (1986)
- “Product” vs. “Process” based regulation

Coordinated Framework for Regulation of Biotechnology (1986)

- Overarching policy document from the Office of Science and Technology Policy (OSTP), across applicable agencies in the US Government (USG)
- Announced the USG policy on regulation of products of biotechnology
- Agencies (e.g., FDA, EPA, USDA, NIH) will seek to operate in an integrated and coordinated fashion

Coordinated Framework

USG role relative to products of biotechnology:

- The risks of GE organisms (animals) not fundamentally different from those posed by non-GE organisms with similar traits (basis for “product-based regulation”)
- Existing laws provide adequate authority
- Regulation should be science based and conducted on a case-by-case basis

FDA Policy Statement, Coordinated Framework

- “FDA Regulation must be based on rational and scientific evaluation of products and not on *a priori* assumptions of certain processes.”
- “ ...is conducted in the light of the intended use of the product on a case-by-case basis.”

Regulatory Documents

- Statute
 - Federal Food, Drug, and Cosmetic Act (FD&C Act)
 - National Environmental Policy Act (NEPA)
- Regulations
 - Code of Federal Regulations (CFR; 21 CFR 511, 514)
 - Implements statute; has force of law
- Guidance for Industry (GFI)
 - FDA's current thinking; advice
 - GFI 187
 - <http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM113903.pdf>

FDA regulates articles, not processes

FD&C Act defines drugs as articles intended to

- Diagnose, cure, mitigate, treat, or prevent disease
- Affect the structure or any function of the body of man or other animals

“Products”

- Applies to those regulated articles, the GE animals produced using the regulated article, and products derived from those animals ...
- GE animals, regardless of intended use:
 - Enhanced growth/efficiency
 - Disease resistance
 - Meat/milk quality/composition
 - Nutrient utilization
 - Biomedical/industrial uses

In contrast ...

- Process-based approaches generally operate from perspective that a given technology presents risks different (e.g., nature, severity) compared to techniques used to produce more “conventional” counterparts

Summary

- FD&C Act, Coordinated Framework as basis for product-based regulation
- FDA & USG – risks of GE vs. non-GE not fundamentally different
- As such, existing statutory/regulatory frameworks provide adequate authority for product-based regulation

Conclusion: USG regulates products of biotechnology, based on “regulatory triggers” in the FD&C Act



Thank you

Harlan Howard, PhD

harlan.howard@fda.hhs.gov

Brinda Dass, PhD

brinda.dass@fda.hhs.gov

Larisa Rudenko, PhD, DABT

larisa.rudenko@fda.hhs.gov